Agios Pharmaceuticals | AGIO - Cash And Equivalent


Agios Pharmaceuticals reported $89.13M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
AbbVie USD 5.23B 400M Dec/2025
Agios Pharmaceuticals USD 89.13M 3.58M Dec/2025
Alnylam Pharmaceuticals USD 1.66B 167M Dec/2025
Amgen USD 9.13B 316M Dec/2025
Arrowhead Research USD 201.64M 112.94M Dec/2025
Astellas Pharma JPY 188.37B 8.51B Mar/2025
AstraZeneca USD 8.14B 1.08B Sep/2025
Bayer EUR 5.9B 1.34B Sep/2025
Biogen USD 3.01B 854.3M Dec/2025
BioMarin Pharmaceutical USD 1.31B 61.57M Dec/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Daiichi Sankyo JPY 542.16B 97.68B Sep/2025
Eli Lilly USD 7.27B 2.52B Dec/2025
Exelixis USD 482.49M 106.19M Dec/2025
Gilead Sciences USD 7.33B 2.19B Sep/2025
GlaxoSmithKline GBP 3.3B 303M Sep/2025
Incyte USD 3.58B 650.78M Dec/2025
Ionis Pharmaceuticals USD 2.24B 1.94B Sep/2025
Merck USD 18.17B 10.16B Sep/2025
Moderna USD 2.6B 1.46B Dec/2025
Nektar Therapeutics USD 41.03M 1.96M Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Pfizer USD 1.34B 295M Sep/2025
Puma Biotechnology USD 53.52M 1.14M Sep/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sarepta Therapeutics USD 613.08M 102.48M Sep/2025
Vertex Pharmaceuticals USD 6.61B 321.1M Dec/2025